35939-60-7

Basic information

• Product Name: 2-AMINO-BETA-L-ARABINOFURANO[1',2':4,5]OXAZOLINE
• Synonyms: 2-AMINO-BETA-L-ARABINOFURANO[1',2':4,5]OXAZOLINE;2-Amino-b-L-arabinofurano[1,2:4,5]oxazoline;2-AMINO-SS-L-ARABINOFURANO[1'',2'':4,5]OXAZOLINE;(3aS,5S,6S,6aR)-2-amino-5-(hydroxymethyl)-3a,5,6,6a-tetrahydrofuro[2,3-d]oxazol-6-ol
• CAS NO: 35939-60-7
• Molecular Formula: C6H10N2O4
• Molecular Weight: 174.155
• Mol File: 35939-60-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 422.0±55.0 °C(Predicted)
• Appearance: /
• Density: 2.14±0.1 g/cm3(Predicted)
• PKA: 12.91±0.60(Predicted)
• CAS DataBase Reference: 2-AMINO-BETA-L-ARABINOFURANO[1',2':4,5]OXAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-BETA-L-ARABINOFURANO[1',2':4,5]OXAZOLINE(35939-60-7)
• EPA Substance Registry System: 2-AMINO-BETA-L-ARABINOFURANO[1',2':4,5]OXAZOLINE(35939-60-7)

Safety Data

• Hazardous Substances Data: 35939-60-7(Hazardous Substances Data)

Usage

Properties

1. Molecular formula: C5H7NO3
2. Molecular weight: 129.11 g/mol
3. Heterocyclic compound
4. Features a furan and an oxazoline ring

Specific content

1. Chemical compound: 2-AMINO-BETA-L-ARABINOFURANO[1',2':4,5]OXAZOLINE
2. Other names: Ara-oxazoline, L-(+)-Ara-oxazoline
3. Uses: Reactant in synthesis of pharmaceuticals and organic compounds
4. Study: Potential biological and pharmacological properties, particularly in antitumor and antiviral research.

Upstream product

• 87-72-9 L-(+)-arabinose 
• 420-04-2 CYANAMID 
• 20074-49-1 β-L-arabinofuranoside 
• 532-20-7 L-arabinose 
• 41546-21-8 L-ribose 

Downstream Products

• 31501-46-9 (2S,3S,3aR,9aS)-3-hydroxy-2-(hydroxymethyl)-2,3,3a,9a-tetrahydro-6H-furo[2,3’:4,5]oxazolo[3,2-a]pyrimidin-6-one 
• 622785-69-7 1-((2S,3S,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 433733-92-7 L-2,2'-anhydro-5-methyluridine 
• 156969-24-3 Thiocarbonic acid O-[(2S,3S,4S,5S)-2-(tert-butyl-dimethyl-silanyloxymethyl)-4-chloro-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl] ester O-phenyl ester 
• 58-96-8 1-(β-L-arabinofuranosyl)-uracil 
• 58-96-8 L-uridine 
• 1748-04-5 (2S,3S,4S,5S)-2-((benzoyloxy)methyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 31615-96-0 3',5'-di-O-benzoyl-2,2'-anhydro-L-uridine 
• 36959-85-0 6-Methoxycarbonyl-O(2,2')-anhydro-L-uridin (L-III) 
• 42188-34-1 N,O³,O⁵-tribenzoyl-N,O²-carbonimidoyl-β-L-arabinofuranosylamine 

Relevant articles and documents

MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

Novel antiviral activity of l-dideoxy bicyclic nucleoside analogues versus vaccinia and measles viruses in vitro

Dideoxy bicyclic pyrimidine nucleoside analogues (ddBCNAs) with d-chirality have previously been described by us to inhibit replication of human cytomegalovirus. We herein report for the first time that activity against vaccinia virus (VACV) was achieved

Synthesis of beta-L-2'-deoxy nucleosides

An improved process for the preparation of 2′-modified nucleosides and 2′-deoxy-nucleosides, such as, β-L-2′-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2′-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2′-anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2′-anhydro-1-furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2′-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2′-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and/or antineoplastic agents.